Patents Assigned to Intellect Neurosciences Inc.
  • Patent number: 8703137
    Abstract: The invention is directed to methods of treatment of Alzheimer's disease and other tauopathies, via the administration of antibodies having specificity to abnormal forms of tau protein, the antibodies showing no binding and/or reactivity to a normal tau protein and being administered under conditions and in amounts effective to prevent or treat Alzheimer's disease or other tauopathies. In certain embodiments, the antibodies are selective for soluble truncated tau protein truncated at (i) its C-terminus after the glutamic acid residue Glu391, or (ii) at the aspartic acid residue Asp421, or (iii) at its N-terminus at the aspartic acid residue Asp13, or (iv) a combination of (i)-(iii). Further aspects of the invention are directed to the administration of an immunogen comprising an abnormal tau, preferably a soluble truncated tau.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: April 22, 2014
    Assignee: Intellect Neurosciences Inc.
    Inventor: Daniel G. Chain
  • Patent number: 8697076
    Abstract: Antibodies selective for pathological tau dimers and/or prefibrillar pathological tau oligomers, immunogenic peptides and epitopes of these antibodies, hydridomas producing these antibodies, uses of these antibodies, immunogenic peptides and epitopes in preparation of pharmaceutical compositions for the treatment of tauopathies, and uses of these antibodies, immunogenic peptides, epitopes and pharmaceutical compositions in the treatment of tauopathies are described. Also described are uses of these antibodies, immunogenic peptides, epitopes in diagnosis and monitoring of tauopathies.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: April 15, 2014
    Assignees: Northwestern University, Intellect Neurosciences Inc.
    Inventors: Lester I. Binder, Daniel G. Chain, Yifan Fu, Kristina Patterson
  • Patent number: 8338379
    Abstract: An antibody capable of recognizing amyloid ? while not recognizing amyloid ? precursor proteins, and a method for using the same. A monoclonal antibody characterized by being capable of recognizing the N-terminus peptide of amyloid ? while not recognizing amyloid ? precursor proteins, an amyloid ? assay kit, a therapeutic agent of Alzheimer's disease, and a method for treating Alzheimer's disease using the monoclonal antibody.
    Type: Grant
    Filed: September 23, 2010
    Date of Patent: December 25, 2012
    Assignee: Intellect Neurosciences, Inc.
    Inventors: Haruyasu Yamaguchi, Noriaki Kinoshita, Masahiro Maeda, Yuko Horikoshi
  • Patent number: 8173127
    Abstract: The invention relates to methods of treating a subject having Alzheimer's Disease, comprising the step of administering an antibody molecule which is targeted to ? amyloid peptide or to fragment thereof. In another embodiment the invention relates to methods of treating a disease or a disorder, characterized by amyloid beta deposition. In another embodiment, the invention relates to an antibody molecule, which is free end-specific for the N-terminus or the C-terminus of an amyloid ? peptide and to a pharmaceutical composition thereof. In another embodiment, the invention relates to an antibody molecule, which is targeted to the free C or N-terminus of a N-and/or C-terminus truncated amyloid ? peptide fragment.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: May 8, 2012
    Assignee: Intellect Neurosciences, Inc.
    Inventor: Daniel G. Chain
  • Patent number: 7901689
    Abstract: The invention provides a chimeric peptide or mixture of chimeric peptides that can be formulated as an immunizing composition and used in a method for immunization of a mammal against an internal peptide cleavage product derived from a precursor or mature protein, for which the peptide cleavage product and the precursor or mature protein are self molecules. The chimeric peptide or peptides have an end-specific B cell epitope from a naturally-occurring internal peptide cleavage product of a precursor or mature protein, as a free N- or C-terminus, fused with or without spacer residues to a T helper cell epitope derived from a living source different from that of the internal peptide cleavage product.
    Type: Grant
    Filed: December 8, 2000
    Date of Patent: March 8, 2011
    Assignee: Intellect Neurosciences, Inc.
    Inventor: Benjamin Chain
  • Patent number: 7807157
    Abstract: An antibody capable of recognizing amyloid ? while not recognizing amyloid ? precursor proteins, and a method for using the same. A monoclonal antibody characterized by being capable of recognizing the N-terminus peptide of amyloid ? while not recognizing amyloid ? precursor proteins, an amyloid ? assay kit, a therapeutic agent of Alzheimer's disease, and a method for treating Alzheimer's disease using the monoclonal antibody.
    Type: Grant
    Filed: September 16, 2004
    Date of Patent: October 5, 2010
    Assignee: Intellect Neurosciences Inc.
    Inventors: Haruyasu Yamaguchi, Noriaki Kinoshita, Masahiro Maeda, Yuko Horikoshi
  • Publication number: 20090069258
    Abstract: DNA encoding a recombinant antibody molecule end-specific for an amyloid-beta peptide, pharmaceutical compositions thereof, and a method for preventing or inhibiting progression of Alzheimer's Disease by introducing such a DNA molecule into brain cells to express the recombinant antibody molecule and prevent the accumulation of amyloid-beta peptides in the cerebrospinal fluid.
    Type: Application
    Filed: May 8, 2007
    Publication date: March 12, 2009
    Applicant: Intellect Neurosciences Inc.
    Inventor: Daniel G. Chain
  • Publication number: 20080207731
    Abstract: Substantially pure 3-(3-indolyl)propionic acid free acid is synthesized by converting the free acid to 3-(3-indolyl)propionic acid calcium salt (3-IPA calcium), precipitating and washing, and then reconverting the 3-IPA calcium to the free acid. 3-IPA calcium is suitable for use in pharmaceutical compositions in tablet and sustained-release dosage forms. 3-IPA calcium can be used to inhibit the cytotoxic effects of amyloid beta protein on cells, to treat fibrillogenic diseases in a mammal, and to treat diseases or conditions in which free radicals or oxidative stress plays a role.
    Type: Application
    Filed: August 23, 2007
    Publication date: August 28, 2008
    Applicant: Intellect Neurosciences, Inc.
    Inventor: Norman H. Rogers